Vaderis Therapeutics

Biotech · Rare Disease Therapeutics · Vascular Disease

Funding

Vaderis raises $152M Series B, starts Phase 3 trial for rare bleeding disorder

The oversubscribed round reflects investors' growing appetite for late-stage rare-disease bets as early biotech funding dries up.

• Vaderis Therapeutics closed an oversubscribed $152 million Series B financing on August 11, 2026, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX.
• The Basel-based clinical-stage biotech is developing engasertib, an oral AKT1/2 inhibitor positioned as the first therapy specifically for hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder with no approved treatments.
• The proceeds fund initiation of the global Phase 3 HEROIC study, a randomized, double-blind, placebo-controlled trial of once-daily engasertib in moderate-to-severe HHT across North America, South America and Europe.
• EQT Life Sciences contributed $17.5 million of the round through one of its managed funds and will join Vaderis' board as an observer.
• Vaderis acquired engasertib from Belfast-based Almac Discovery in 2020 and emerged from stealth in 2022 already holding the once-daily drug candidate.
• A prior 75-patient Phase 2 proof-of-concept study published in the New England Journal of Medicine found engasertib reduced epistaxis frequency and duration versus placebo, the basis for advancing to Phase 3.
• The deal underscores investors' pivot toward de-risked, pivotal-stage rare-disease programs as early-stage venture funding for biotech tightens industry-wide.